XOMA Royalty Corp (XOMA) 8-K Current Report: March 18, 2026
Filed: March 18, 2026
Health Care
Pharmaceutical PreparationsXOMA Royalty Corp (XOMA) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
XOMA Royalty Corp 8-K Mar 18, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Reporting period covers fiscal quarter and year ended December 31, 2025
- • Financial results disclosed via press release in Exhibit 99.1
- • Investors should review Exhibit 99.1 for detailed performance metrics and guidance
- • Indicates timely earnings communication consistent with disclosure obligations
Item 7.01 · Regulation FD Disclosure
- • Updated corporate presentation released on March 18, 2026, providing latest company information and strategy
- • Presentation included as Exhibit 99.2 in the current 8-K filing for investor review
- • Information provided is for disclosure purposes, not legally “filed” or subject to Exchange Act liability
- • No financial or operational updates detailed in this disclosure, focus on investor communication and transparency
Other XOMA Royalty Corp 8-K Filings
Get deeper insights on XOMA Royalty Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.